EW - Edwards Lifesciences projects $5.5 - $6.0 billion global sales in 2022

Ahead of its annual investor conference scheduled for today, Edwards Lifesciences (EW +1.7%) has reaffirmed its previously issued financial guidance for 2021. The health care equipment maker also announced its 2022 financial guidance indicating $5.5 - $6.0 billion in global sales for the year to imply an underlying growth rate of low double-digits. The sales from Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments are expected to reach $3.7 - $4.0 billion and $140 - $170 million in 2022, respectively. The adjusted earnings per share for the year are estimated at $2.50 - $2.65. In 2022, Edwards Lifesciences (NYSE:EW) expects to start its ALLIANCE pivotal trial for next-gen SAPIEN X4, and late in the year, it anticipates the U.S. approval for PASCAL for patients with degenerative mitral regurgitation. The European approval for the EVOQUE tricuspid valve is also expected in late 2022. Edwards Lifesciences (EW)

For further details see:

Edwards Lifesciences projects $5.5 - $6.0 billion global sales in 2022